Cantargia AB (CANTA)

Stockholm
Currency in SEK
1.17
0.00(0.00%)
Real-time Data·
CANTA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CANTA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.121.20
52 wk Range
1.004.79
Key Statistics
Edit
Prev. Close
1.17
Open
1.18
Day's Range
1.12-1.2
52 wk Range
1-4.79
Volume
649.93K
Average Volume (3m)
893.72K
1-Year Change
-74.06%
Book Value / Share
0.28
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CANTA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.50
Upside
+370.09%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Cantargia AB News & Analysis

Show more

Cantargia AB Company Profile

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.

Cantargia AB Earnings Call Summary for Q1/2025

  • Cantargia AB reported Q1 2025 operating loss of SEK 45M, stock down 6.02%; cash position SEK 104M to support operations until Q4 2025
  • CAN10 phase one studies completed with full receptor occupancy; phase two studies in HS and AD planned for end of 2025
  • Nadunolumab trials progressing with completed recruitment; results expected mid-2025; company seeking additional financing
  • R&D expenses up 6% YoY to SEK 45-41M; company faces financial challenges amid competitive biotech landscape
  • Stock trading between 52-week high of $0.53 and low of $0.12; analyst targets $0.51-$0.69; EPS forecast -$0.07 for FY2025
Last Updated: 13/05/2025, 15:24
Read Full Transcript

Compare CANTA to Peers and Sector

Metrics to compare
CANTA
Peers
Sector
Relationship
P/E Ratio
−1.7x−10.6x−0.5x
PEG Ratio
−0.04−0.190.00
Price/Book
4.1x5.5x2.6x
Price / LTM Sales
-60.2x3.0x
Upside (Analyst Target)
370.1%103.2%52.6%
Fair Value Upside
Unlock10.1%8.7%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 5.50
(+370.09% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.19 / --
Revenue / Forecast
13.60M / --
EPS Revisions
Last 90 days

CANTA Income Statement

FAQ

What Stock Exchange Does Cantargia AB Trade On?

Cantargia AB is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Cantargia AB?

The stock symbol for Cantargia AB is "CANTA."

What Is the Cantargia AB Market Cap?

As of today, Cantargia AB market cap is 290.88M.

What Is Cantargia AB's Earnings Per Share (TTM)?

The Cantargia AB EPS (TTM) is -0.86.

When Is the Next Cantargia AB Earnings Date?

Cantargia AB will release its next earnings report on 20 Aug 2025.

From a Technical Analysis Perspective, Is CANTA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Cantargia AB Stock Split?

Cantargia AB has split 2 times.

How Many Employees Does Cantargia AB Have?

Cantargia AB has 22 employees.

What is the current trading status of Cantargia AB (CANTA)?

As of 23 Jun 2025, Cantargia AB (CANTA) is trading at a price of 1.17, with a previous close of 1.17. The stock has fluctuated within a day range of 1.12 to 1.20, while its 52-week range spans from 1.00 to 4.79.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.